Cargando…

Development and validation of the self-administered Fibromyalgia Assessment Status: a disease-specific composite measure for evaluating treatment effect

INTRODUCTION: The Fibromyalgia Impact Questionnaire (FIQ) is a composite disease-specific measure validated for fibromyalgia (FM), but it is rarely used in clinical practice. The objective was to develop and analyse the psychometric properties of a new composite disease-specific index (Fibromyalgia...

Descripción completa

Detalles Bibliográficos
Autores principales: Salaffi, Fausto, Sarzi-Puttini, Piercarlo, Girolimetti, Rita, Gasparini, Stefania, Atzeni, Fabiola, Grassi, Walter
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2745809/
https://www.ncbi.nlm.nih.gov/pubmed/19686606
http://dx.doi.org/10.1186/ar2792
_version_ 1782172004098506752
author Salaffi, Fausto
Sarzi-Puttini, Piercarlo
Girolimetti, Rita
Gasparini, Stefania
Atzeni, Fabiola
Grassi, Walter
author_facet Salaffi, Fausto
Sarzi-Puttini, Piercarlo
Girolimetti, Rita
Gasparini, Stefania
Atzeni, Fabiola
Grassi, Walter
author_sort Salaffi, Fausto
collection PubMed
description INTRODUCTION: The Fibromyalgia Impact Questionnaire (FIQ) is a composite disease-specific measure validated for fibromyalgia (FM), but it is rarely used in clinical practice. The objective was to develop and analyse the psychometric properties of a new composite disease-specific index (Fibromyalgia Assessment Status, FAS), a simple self-administered index that combines a patient's assessment of fatigue, sleep disturbances and pain evaluated on the basis of the 16 non-articular sites listed on the Self-Assessment Pain Scale (SAPS) in a single measure (range 0 to 10). METHODS: The FAS index was constructed using a traditional development strategy, and its psychometric properties were tested in 226 FM patients (209 women, 17 men); whose disease-related characteristics were assessed by means of an 11-numbered circular numerical rating scale (NRS) for pain, fatigue, sleep disturbances and general health (GH), the tender point score (TPS), the SAPS, the FIQ, and the SF-36. A group of 226 rheumatoid arthritis (RA) patients was used for comparative purposes. Of the 179 FM patients who entered the follow-up study, 152 completed the three-month period and were included in the responsiveness analyses. One hundred and fifty-four patients repeated the FAS questionnaire after an interval of one week, and its test/re-test reliability was calculated. Responsiveness was evaluated on the basis of effect size and the standardised response mean. RESULTS: The FAS index fulfilled the established criteria for validity, reliability and responsiveness. Factor analysis showed that SAPS and fatigue contributed most, and respectively explained 47.4% and 31.2% of the variance; sleep explained 21.3%. Testing for internal consistency showed that Cronbach's alpha was 0.781, thus indicating a high level of reliability. As expected, closer significant correlations were found when FAS was compared with total FIQ (rho = 0.347; P < 0.0001) and the FIQ subscales, particularly job ability, tiredness, fatigue and pain (all P < 0.0001), but the correlation between FAS and the mental component summary scale score (MCS) of the SF-36 (rho = -0.531; P < 0.0001) was particularly interesting. Test/re-test reliability was satisfactory. The FAS showed the greatest effect size. The magnitude of the responsiveness measures was statistically different between FAS (0.889) and the FIQ (0.781) (P = 0.038), and between the SF-36 MCS (0.434) and the SF-36 physical component summary scale score (PCS) (0.321) (P < 0.01). CONCLUSIONS: The self-administered FAS is a reliable, valid and responsive disease-specific composite measure for assessing treatment effect in patients with FM.
format Text
id pubmed-2745809
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27458092009-09-18 Development and validation of the self-administered Fibromyalgia Assessment Status: a disease-specific composite measure for evaluating treatment effect Salaffi, Fausto Sarzi-Puttini, Piercarlo Girolimetti, Rita Gasparini, Stefania Atzeni, Fabiola Grassi, Walter Arthritis Res Ther Research Article INTRODUCTION: The Fibromyalgia Impact Questionnaire (FIQ) is a composite disease-specific measure validated for fibromyalgia (FM), but it is rarely used in clinical practice. The objective was to develop and analyse the psychometric properties of a new composite disease-specific index (Fibromyalgia Assessment Status, FAS), a simple self-administered index that combines a patient's assessment of fatigue, sleep disturbances and pain evaluated on the basis of the 16 non-articular sites listed on the Self-Assessment Pain Scale (SAPS) in a single measure (range 0 to 10). METHODS: The FAS index was constructed using a traditional development strategy, and its psychometric properties were tested in 226 FM patients (209 women, 17 men); whose disease-related characteristics were assessed by means of an 11-numbered circular numerical rating scale (NRS) for pain, fatigue, sleep disturbances and general health (GH), the tender point score (TPS), the SAPS, the FIQ, and the SF-36. A group of 226 rheumatoid arthritis (RA) patients was used for comparative purposes. Of the 179 FM patients who entered the follow-up study, 152 completed the three-month period and were included in the responsiveness analyses. One hundred and fifty-four patients repeated the FAS questionnaire after an interval of one week, and its test/re-test reliability was calculated. Responsiveness was evaluated on the basis of effect size and the standardised response mean. RESULTS: The FAS index fulfilled the established criteria for validity, reliability and responsiveness. Factor analysis showed that SAPS and fatigue contributed most, and respectively explained 47.4% and 31.2% of the variance; sleep explained 21.3%. Testing for internal consistency showed that Cronbach's alpha was 0.781, thus indicating a high level of reliability. As expected, closer significant correlations were found when FAS was compared with total FIQ (rho = 0.347; P < 0.0001) and the FIQ subscales, particularly job ability, tiredness, fatigue and pain (all P < 0.0001), but the correlation between FAS and the mental component summary scale score (MCS) of the SF-36 (rho = -0.531; P < 0.0001) was particularly interesting. Test/re-test reliability was satisfactory. The FAS showed the greatest effect size. The magnitude of the responsiveness measures was statistically different between FAS (0.889) and the FIQ (0.781) (P = 0.038), and between the SF-36 MCS (0.434) and the SF-36 physical component summary scale score (PCS) (0.321) (P < 0.01). CONCLUSIONS: The self-administered FAS is a reliable, valid and responsive disease-specific composite measure for assessing treatment effect in patients with FM. BioMed Central 2009 2009-08-18 /pmc/articles/PMC2745809/ /pubmed/19686606 http://dx.doi.org/10.1186/ar2792 Text en Copyright © 2009 Salaffi et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Salaffi, Fausto
Sarzi-Puttini, Piercarlo
Girolimetti, Rita
Gasparini, Stefania
Atzeni, Fabiola
Grassi, Walter
Development and validation of the self-administered Fibromyalgia Assessment Status: a disease-specific composite measure for evaluating treatment effect
title Development and validation of the self-administered Fibromyalgia Assessment Status: a disease-specific composite measure for evaluating treatment effect
title_full Development and validation of the self-administered Fibromyalgia Assessment Status: a disease-specific composite measure for evaluating treatment effect
title_fullStr Development and validation of the self-administered Fibromyalgia Assessment Status: a disease-specific composite measure for evaluating treatment effect
title_full_unstemmed Development and validation of the self-administered Fibromyalgia Assessment Status: a disease-specific composite measure for evaluating treatment effect
title_short Development and validation of the self-administered Fibromyalgia Assessment Status: a disease-specific composite measure for evaluating treatment effect
title_sort development and validation of the self-administered fibromyalgia assessment status: a disease-specific composite measure for evaluating treatment effect
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2745809/
https://www.ncbi.nlm.nih.gov/pubmed/19686606
http://dx.doi.org/10.1186/ar2792
work_keys_str_mv AT salaffifausto developmentandvalidationoftheselfadministeredfibromyalgiaassessmentstatusadiseasespecificcompositemeasureforevaluatingtreatmenteffect
AT sarziputtinipiercarlo developmentandvalidationoftheselfadministeredfibromyalgiaassessmentstatusadiseasespecificcompositemeasureforevaluatingtreatmenteffect
AT girolimettirita developmentandvalidationoftheselfadministeredfibromyalgiaassessmentstatusadiseasespecificcompositemeasureforevaluatingtreatmenteffect
AT gasparinistefania developmentandvalidationoftheselfadministeredfibromyalgiaassessmentstatusadiseasespecificcompositemeasureforevaluatingtreatmenteffect
AT atzenifabiola developmentandvalidationoftheselfadministeredfibromyalgiaassessmentstatusadiseasespecificcompositemeasureforevaluatingtreatmenteffect
AT grassiwalter developmentandvalidationoftheselfadministeredfibromyalgiaassessmentstatusadiseasespecificcompositemeasureforevaluatingtreatmenteffect